News Releases
All Releases
View Summary Peregrine Reports Promising 20.7 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial
Aug 24, 2011
PDF 18.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Recent Developments
Jul 14, 2011
PDF 30.3 KB Add to Briefcase
View Summary Peregrine to Report Fourth Quarter and Fiscal Year 2011 Financial Results After Market Close on July 14, 2011
Jul 7, 2011
PDF 13.7 KB Add to Briefcase
View Summary Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung Cancer
Jun 15, 2011
PDF 19.1 KB Add to Briefcase
View Summary Peregrine Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara at ASCO Annual Meeting
Jun 3, 2011
PDF 19.8 KB Add to Briefcase
View Summary Peregrine Appoints Jeffrey Masten as Vice President, Quality as Company Advances Phase II Clinical Programs
May 31, 2011
PDF 16.3 KB Add to Briefcase
View Summary Keynote Presentation at Leading European Antibody Conference Highlights Immune Reactivation Mechanisms of Bavituximab
May 26, 2011
PDF 19.4 KB Add to Briefcase
View Summary Peregrine Announces Initiation of Phase I/II Prostate Cancer Investigator-Sponsored Trial (IST)
May 25, 2011
PDF 20.2 KB Add to Briefcase
View Summary Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
May 19, 2011
PDF 20.9 KB Add to Briefcase
View Summary Four AACR Presentations Highlight Broad Therapeutic and Diagnostic Potential of Peregrine's First-in-Class PS-Targeting Platform
Apr 6, 2011
PDF 59.6 KB Add to Briefcase
View Summary Peregrine's PS-Targeting Antibody Significantly Improves Anti-Tumor Effect of Sorafenib in Models of Advanced Liver Cancer
Apr 5, 2011
PDF 22.6 KB Add to Briefcase
View Summary Peregrine Presents Phase Ib HCV/HIV Data on Single-Agent Bavituximab at EASL
Apr 4, 2011
PDF 67.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2011 Financial Results and Recent Developments
Mar 11, 2011
PDF 28.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at Roth Capital Partners OC Growth Stock Conference
Mar 10, 2011
PDF 14.8 KB Add to Briefcase
View Summary Peregrine Appoints Head of Medical Oncology as Company Advances Four Randomized Phase II Trials
Mar 9, 2011
PDF 15.9 KB Add to Briefcase
View Summary Peregrine Announces Initiation of Lung Cancer Investigator-Sponsored Trial
Mar 8, 2011
PDF 19.8 KB Add to Briefcase
View Summary Peregrine's Bavituximab HCV Abstract Accepted for Presentation at the 46th Annual Meeting of EASL
Mar 7, 2011
PDF 14.7 KB Add to Briefcase
View Summary Peregrine to Report Third Quarter Fiscal Year 2011 Financial Results After Market Close on March 11, 2011
Mar 4, 2011
PDF 13.7 KB Add to Briefcase
View Summary Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting
Feb 28, 2011
PDF 20.0 KB Add to Briefcase
View Summary Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection Trial
Jan 31, 2011
PDF 19.5 KB Add to Briefcase
Showing 1-20 of 437 Page: 1 2 3 4 5 ... 22 Next 20
Add to Briefcase = add release to Briefcase
Print E-mail